ATE449769T1 - 3-(4-ää4-(4ää3-(3,3-dimethyl-1- piperidinyl)propyläoxyüphinylü-1- piperidinylcarbonylü-1-naphthalinyl)propan- oder propensäure als h1- und h3-rezeptor-antagonisten zur behandlung entzündlicher und/oder allergischer erkrankungen - Google Patents

3-(4-ää4-(4ää3-(3,3-dimethyl-1- piperidinyl)propyläoxyüphinylü-1- piperidinylcarbonylü-1-naphthalinyl)propan- oder propensäure als h1- und h3-rezeptor-antagonisten zur behandlung entzündlicher und/oder allergischer erkrankungen

Info

Publication number
ATE449769T1
ATE449769T1 AT06841477T AT06841477T ATE449769T1 AT E449769 T1 ATE449769 T1 AT E449769T1 AT 06841477 T AT06841477 T AT 06841477T AT 06841477 T AT06841477 T AT 06841477T AT E449769 T1 ATE449769 T1 AT E449769T1
Authority
AT
Austria
Prior art keywords
propyläoxyüphinylü
propeneic
piperidinylcarbonylü
naphthalinyl
piperidinyl
Prior art date
Application number
AT06841477T
Other languages
English (en)
Inventor
Simon Hodgson
Panayiotis Procopiou
Brugarolas Maria Vinader
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0525897A external-priority patent/GB0525897D0/en
Priority claimed from GB0623217A external-priority patent/GB0623217D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE449769T1 publication Critical patent/ATE449769T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06841477T 2005-12-20 2006-12-19 3-(4-ää4-(4ää3-(3,3-dimethyl-1- piperidinyl)propyläoxyüphinylü-1- piperidinylcarbonylü-1-naphthalinyl)propan- oder propensäure als h1- und h3-rezeptor-antagonisten zur behandlung entzündlicher und/oder allergischer erkrankungen ATE449769T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0525897A GB0525897D0 (en) 2005-12-20 2005-12-20 Compounds
GB0623217A GB0623217D0 (en) 2006-11-21 2006-11-21 Compounds
PCT/EP2006/069943 WO2007071691A1 (en) 2005-12-20 2006-12-19 3- (4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] 0xy} phenyl) -1-piperidinyl] carbonyl }-1-naphthalenyl) propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders

Publications (1)

Publication Number Publication Date
ATE449769T1 true ATE449769T1 (de) 2009-12-15

Family

ID=37845266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841477T ATE449769T1 (de) 2005-12-20 2006-12-19 3-(4-ää4-(4ää3-(3,3-dimethyl-1- piperidinyl)propyläoxyüphinylü-1- piperidinylcarbonylü-1-naphthalinyl)propan- oder propensäure als h1- und h3-rezeptor-antagonisten zur behandlung entzündlicher und/oder allergischer erkrankungen

Country Status (24)

Country Link
US (1) US7989629B2 (de)
EP (2) EP1963307B1 (de)
JP (2) JP4445570B2 (de)
KR (1) KR20080087102A (de)
AR (1) AR058109A1 (de)
AT (1) ATE449769T1 (de)
AU (1) AU2006328512B2 (de)
BR (1) BRPI0620218A2 (de)
CA (1) CA2634391A1 (de)
CR (1) CR10102A (de)
CY (1) CY1110601T1 (de)
DE (1) DE602006010737D1 (de)
DK (1) DK1963307T3 (de)
EA (1) EA014354B1 (de)
ES (1) ES2337187T3 (de)
IL (1) IL191967A0 (de)
MA (1) MA30373B1 (de)
NO (1) NO20082695L (de)
PE (1) PE20071068A1 (de)
PL (1) PL1963307T3 (de)
PT (1) PT1963307E (de)
SI (1) SI1963307T1 (de)
TW (1) TW200730498A (de)
WO (1) WO2007071691A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019819B1 (ru) 2008-05-23 2014-06-30 ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении
WO2011000765A1 (en) 2009-06-29 2011-01-06 Glaxo Group Limited New medical use
JP4785963B2 (ja) 2009-10-09 2011-10-05 キヤノン株式会社 固体撮像装置
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
KR20170003673A (ko) 2014-05-12 2017-01-09 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 감염성 질환을 치료하기 위한 다니릭신을 포함하는 약제 조성물
KR101640756B1 (ko) 2014-10-28 2016-07-19 이종찬 전동 드릴 장착용 내시경 캡
WO2019169082A1 (en) * 2018-03-01 2019-09-06 Ferox Therapeutics Llc Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients
JP2023519585A (ja) 2020-03-26 2023-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ウイルス感染を予防または治療するカテプシン阻害剤

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
NZ251092A (en) 1992-04-02 1996-12-20 Smithkline Beecham Corp 4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DE69334150T2 (de) 1992-05-14 2008-03-13 Baylor College Of Medicine, Houston Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
CN1070849C (zh) 1994-06-15 2001-09-12 惠尔康基金会集团公司 酶抑制剂
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
HK1043788A1 (zh) 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
JP4436041B2 (ja) 2000-08-05 2010-03-24 グラクソ グループ リミテッド 抗炎症剤としての6α,9α−ジフルオロ−17α−[(2−フラニルカルボキシル)オキシ]−11β−ヒドロキシ−16α−メチル−3−オキソ−アンドロスト−1,4−ジエン−17−チオカルボン酸S−フルオロメチルエステル
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
SI1425001T1 (sl) 2001-09-14 2009-04-30 Glaxo Group Ltd Glaxo Welcome Fenetanolaminski derivati za zdravljenje respiratornih bolezni
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
ES2276038T3 (es) 2002-01-14 2007-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para su obtencion, formulaciones farmaceuticas que los contienen y usos de los mismos.
WO2003061651A1 (en) 2002-01-22 2003-07-31 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP4324480B2 (ja) 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
ATE496620T1 (de) 2002-04-11 2011-02-15 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE60318193T2 (de) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体の修飾物質および方法
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003298094A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Medicinal arylethanolamine compounds
JP2006512404A (ja) * 2002-10-22 2006-04-13 グラクソ グループ リミテッド H3受容体リガンドとしてのアリールオキシアルキルアミン誘導体
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
EP1556342B1 (de) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US7465795B2 (en) 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
KR20090007604A (ko) 2006-04-20 2009-01-19 글락소 그룹 리미티드 히스타민 h1 및 h3 길항제로서의 2―치환된 4―벤질프탈라지논 유도체

Also Published As

Publication number Publication date
CR10102A (es) 2008-09-22
PT1963307E (pt) 2010-03-03
HK1120265A1 (en) 2009-03-27
SI1963307T1 (sl) 2010-03-31
PE20071068A1 (es) 2007-12-13
DK1963307T3 (da) 2010-04-06
CA2634391A1 (en) 2007-06-28
NO20082695L (no) 2008-09-16
EP1963307B1 (de) 2009-11-25
US7989629B2 (en) 2011-08-02
EP1963307A1 (de) 2008-09-03
EA200801342A1 (ru) 2008-12-30
MA30373B1 (fr) 2009-05-04
PL1963307T3 (pl) 2010-05-31
US20080312280A1 (en) 2008-12-18
WO2007071691A1 (en) 2007-06-28
AU2006328512A1 (en) 2007-06-28
JP2009520001A (ja) 2009-05-21
DE602006010737D1 (de) 2010-01-07
ES2337187T3 (es) 2010-04-21
EA014354B1 (ru) 2010-10-29
TW200730498A (en) 2007-08-16
IL191967A0 (en) 2008-12-29
JP2009235087A (ja) 2009-10-15
JP4445570B2 (ja) 2010-04-07
KR20080087102A (ko) 2008-09-30
CY1110601T1 (el) 2015-04-29
AR058109A1 (es) 2008-01-23
EP2157087A1 (de) 2010-02-24
AU2006328512B2 (en) 2011-06-23
BRPI0620218A2 (pt) 2011-11-01

Similar Documents

Publication Publication Date Title
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
EP1898930A4 (de) Behandlung von entzündlichen erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
IL183827A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
EP1804761A4 (de) Zusammensetzungen und verfahren zur behandlung von hautverfärbungen
DE602007005120D1 (de) 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE495179T1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EP2418961A4 (de) Milch-oligosaccharid-zusammensetzung und ihre verwendung bei der behandlung von infektionen bei tieren
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
EP1924269A4 (de) Vegetationswasser-zusammensetzung zur behandlung von entzündlichen hautkrankheiten
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
HRP20150320T1 (xx) Formulacije i metode za lijeäśenje amiloidoze
ATE449769T1 (de) 3-(4-ää4-(4ää3-(3,3-dimethyl-1- piperidinyl)propyläoxyüphinylü-1- piperidinylcarbonylü-1-naphthalinyl)propan- oder propensäure als h1- und h3-rezeptor-antagonisten zur behandlung entzündlicher und/oder allergischer erkrankungen
EP2164517A4 (de) Il-18 und protein-kinase-r-hemmung zur behandlung von copd
BRPI0809970A2 (pt) Antagonistas de cxcl 13 e seu uso para o tratamento de doenças inflamatórias
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
EP1773779A4 (de) Nicotinrezeptoragonisten zur behandlung entzündlicher krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1963307

Country of ref document: EP